Anavex Life Sciences Corp. (NASDAQ:AVXL) Holdings Lifted by Nwam LLC

Nwam LLC grew its position in Anavex Life Sciences Corp. (NASDAQ:AVXL) by 0.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 913,051 shares of the biotechnology company’s stock after purchasing an additional 2,575 shares during the period. Nwam LLC’s holdings in Anavex Life Sciences were worth $9,806,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of AVXL. Barclays PLC boosted its holdings in shares of Anavex Life Sciences by 70.4% in the third quarter. Barclays PLC now owns 155,179 shares of the biotechnology company’s stock valued at $882,000 after acquiring an additional 64,101 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of Anavex Life Sciences by 2.3% in the third quarter. Charles Schwab Investment Management Inc. now owns 665,976 shares of the biotechnology company’s stock valued at $3,783,000 after acquiring an additional 14,892 shares in the last quarter. Franklin Resources Inc. boosted its holdings in shares of Anavex Life Sciences by 6.7% in the third quarter. Franklin Resources Inc. now owns 58,557 shares of the biotechnology company’s stock valued at $317,000 after acquiring an additional 3,674 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of Anavex Life Sciences by 2.8% in the third quarter. Geode Capital Management LLC now owns 1,883,199 shares of the biotechnology company’s stock valued at $10,699,000 after acquiring an additional 51,946 shares in the last quarter. Finally, Stratos Wealth Partners LTD. bought a new position in shares of Anavex Life Sciences in the fourth quarter valued at approximately $241,000. Institutional investors own 31.55% of the company’s stock.

Anavex Life Sciences Stock Performance

Shares of NASDAQ:AVXL opened at $8.07 on Thursday. The stock has a market capitalization of $686.43 million, a price-to-earnings ratio of -14.67 and a beta of 0.69. Anavex Life Sciences Corp. has a 1-year low of $3.25 and a 1-year high of $14.44. The company has a 50 day moving average price of $9.92 and a 200 day moving average price of $7.83.

Anavex Life Sciences (NASDAQ:AVXL) last issued its earnings results on Wednesday, February 12th. The biotechnology company reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.03. On average, sell-side analysts expect that Anavex Life Sciences Corp. will post -0.69 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the stock. D. Boral Capital reiterated a “buy” rating and issued a $46.00 price objective on shares of Anavex Life Sciences in a report on Wednesday, February 12th. HC Wainwright reiterated a “buy” rating and issued a $42.00 price objective on shares of Anavex Life Sciences in a report on Tuesday, February 18th.

Anavex Life Sciences Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.